Schizophrenia Research Today is a free monthly online journal that collates and summarizes the latest research about Schizophrenia, including details on paranoia, symptoms, treatment, depression, medication.

Volume 2 (2005), Issue 6 (June)

1. Reduced density of calbindin-immunoreactive interneurons in the planum temporale in schizophrenia.
   Brain Res, 1046(1): 32-7. [Abstract] [Full-text]
2. Preliminary evidence for reduced social interactions in Chakragati mutants modeling certain symptoms of schizophrenia.
   Brain Res, 1046(1): 180-6. [Abstract] [Full-text]
3. Finding schizophrenia genes.
   J Clin Invest, 115(6): 1440-8. [Abstract] [Full-text]
4. Informed consent in medication-free schizophrenia research.
   Am J Psychiatry, 162(6): 1209-11. [Abstract] [Full-text]
5. Executive function and cognitive subprocesses in first-episode, drug-naive schizophrenia: an analysis of N-back performance.
   Am J Psychiatry, 162(6): 1206-8. [Abstract] [Full-text]
6. Reduced cerebellar inhibition in schizophrenia: a preliminary study.
   Am J Psychiatry, 162(6): 1203-5. [Abstract] [Full-text]
7. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia.
   Am J Psychiatry, 162(6): 1200-2. [Abstract] [Full-text]
8. Repetitive transcranial magnetic stimulation in schizophrenic patients reporting auditory hallucinations.
   Neurosci Lett, 383(1): 54-7. [Abstract] [Full-text]
9. Media consumption and desire for social distance towards people with schizophrenia.
   Eur Psychiatry, 20(3): 246-50. [Abstract] [Full-text]
10. Relation between estradiol and negative symptoms in men with schizophrenia.
    J Neuropsychiatry Clin Neurosci, 17(2): 239-42. [Abstract] [Full-text]
11. Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia.
    J Neuropsychiatry Clin Neurosci, 17(2): 221-6. [Abstract] [Full-text]
12. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.
    Arch Gen Psychiatry, 62(6): 649-59. [Abstract] [Full-text]
13. Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder.
    Arch Gen Psychiatry, 62(6): 642-8. [Abstract] [Full-text]
14. No association between the ionotropic glutamate receptor kainate 3 gene ser310ala polymorphism and schizophrenia.
    Neuropsychobiology, 51(4): 211-3. [Abstract] [Full-text]
15. Pathways to schizophrenic psychosis: a LISREL-tested model of the unfolding of the schizophrenic prodrome.
    J Clin Psychol, 61(7): 909-38. [Abstract] [Full-text]
16. Relationship between class I and II HLA antigens in schizophrenia and eye movement disturbances: a preliminary study.
    Neuropsychobiology, 51(4): 204-10. [Abstract] [Full-text]
17. Information processing flow and neural activations in the dorsolateral prefrontal cortex in the Stroop task in schizophrenic patients. A spatially filtered MEG analysis with high temporal and spatial resolution.
    Neuropsychobiology, 51(4): 191-203. [Abstract] [Full-text]
18. Individual analysis of EEG band power and clinical drug response in schizophrenia.
    Neuropsychobiology, 51(4): 183-90. [Abstract] [Full-text]
19. Neuropsychological correlates of an attention-related negative component elicited in an auditory oddball paradigm in schizophrenia.
    Neuropsychobiology, 51(4): 177-82. [Abstract] [Full-text]
20. Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients.
    Neuropsychobiology, 51(4): 173-6. [Abstract] [Full-text]
21. The effect of quetiapine on aggression and hostility in patients with schizophrenia.
    Hum Psychopharmacol, 20(4): 237-41. [Abstract] [Full-text]
22. An open study of risperidone liquid in the acute phase of schizophrenia.
    Hum Psychopharmacol, 20(4): 243-8. [Abstract] [Full-text]
23. Self-administered instrument to measure the patient's experience of recovery after first-episode psychosis: development and validation of the Psychosis Recovery Inventory.
    Aust N Z J Psychiatry, 39(6): 493-9. [Abstract] [Full-text]
24. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.
    Aust N Z J Psychiatry, 39(6): 479-86. [Abstract] [Full-text]
25. Executive control of working memory in schizophrenia.
    Psychiatry Res, 135(2): 81-90. [Abstract] [Full-text]
26. Disability in schizophrenia: clinical correlates and prediction over 1-year follow-up.
    Psychiatry Res, 135(2): 103-11. [Abstract] [Full-text]
27. Abnormal subjective experiences of schizophrenia: evaluation of the Eppendorf Schizophrenia Inventory.
    Psychiatry Res, 135(2): 91-101. [Abstract] [Full-text]
28. The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients.
    Ann Clin Biochem, 42: 216-9. [Abstract] [Full-text]
29. Is it necessary to differentiate tinnitus from auditory hallucination in schizophrenic patients?
    J Laryngol Otol, 119(5): 352-5. [Abstract] [Full-text]
30. Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.
    Neuroscience, 133(3): 729-38. [Abstract] [Full-text]
31. Celecoxib augmentation of continuously ill patients with schizophrenia.
    Biol Psychiatry, 57(12): 1594-6. [Abstract] [Full-text]
32. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.
    Biol Psychiatry, 57(12): 1543-9. [Abstract] [Full-text]
33. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB.
    Biol Psychiatry, 57(12): 1510-6. [Abstract] [Full-text]
34. P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment.
    Biol Psychiatry, 57(12): 1504-9. [Abstract] [Full-text]
35. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels.
    Biol Psychiatry, 57(12): 1493-503. [Abstract] [Full-text]
36. Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.
    Acta Psychiatr Scand, 112(1): 75-6; discussion 77. [Abstract] [Full-text]
37. Metacognition amidst narratives of self and illness in schizophrenia: associations with neurocognition, symptoms, insight and quality of life.
    Acta Psychiatr Scand, 112(1): 64-71. [Abstract] [Full-text]
38. Cost of care of schizophrenia: a study of Indian out-patient attenders.
    Acta Psychiatr Scand, 112(1): 54-63. [Abstract] [Full-text]
39. Premorbid adjustment in first episode schizophrenia and schizoaffective disorders: a comparison of social and academic domains.
    Acta Psychiatr Scand, 112(1): 30-9. [Abstract] [Full-text]
40. Breastfeeding and risk of schizophrenia in the Copenhagen Perinatal Cohort.
    Acta Psychiatr Scand, 112(1): 26-9. [Abstract] [Full-text]
41. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia.
    Synapse, 57(3): 123-31. [Abstract] [Full-text]
42. Stereological studies of capillary length density in the frontal cortex of schizophrenics.
    Acta Neuropathol (Berl), 109(5): 510-8. [Abstract] [Full-text]
43. Functional MRI BOLD response to Tower of London performance of first-episode schizophrenia patients using cortical pattern matching.
    Neuroimage, 26(3): 941-51. [Abstract] [Full-text]
44. Delayed hemodynamic responses in schizophrenia.
    Neuroimage, 26(3): 922-31. [Abstract] [Full-text]
45. Immunohistochemical and immunoblot analysis of gamma-aminobutyric acid B receptor in the prefrontal cortex of subjects with schizophrenia and bipolar disorder.
    Neurosci Lett, 383(3): 272-7. [Abstract] [Full-text]
46. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia.
    Proc Natl Acad Sci U S A, 102(24): 8627-32. [Abstract] [Full-text]
47. Recognition and optimal management of schizophrenia and related psychoses.
    Intern Med J, 35(7): 413-8. [Abstract] [Full-text]
48. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity.
    Neuroimage, 26(4): 1109-18. [Abstract] [Full-text]
49. Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia.
    Psychiatry Res, 139(1): 19-30. [Abstract] [Full-text]
50. Fractal dimension of cerebral cortical surface in schizophrenia and obsessive-compulsive disorder.
    Neurosci Lett, 384(1): 172-6. [Abstract] [Full-text]
51. The importance of modelling heterogeneity in complex disease: application to NIMH Schizophrenia Genetics Initiative data.
    Hum Genet, 117(2): 160-7. [Abstract] [Full-text]
52. An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray.
    Eur J Hum Genet, 13(7): 807-14. [Abstract] [Full-text]
53. Reelin promoter hypermethylation in schizophrenia.
    Proc Natl Acad Sci U S A, 102(26): 9341-6. [Abstract] [Full-text]

© 2004-2012 Schizophrenia Research Today. All Rights Reserved.